The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma
Withdrawn
- Conditions
- Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse
- Registration Number
- NCT00498667
- Lead Sponsor
- Rambam Health Care Campus
- Brief Summary
A retrospective analysis will be performed regarding the usefulness of PET/CT performed following 2 cycle of chemotherapy in evaluation of progression, free survival and overall survival of patients with aggressive non Hodgkin Lymphoma.
- Detailed Description
Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT as a predictive value for progression free survival and overall survival is evaluated
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- aggressive non-Hodgkin lymphoma b cells
- age 18-70
- bilirubin less then 2
- creatinine less then 2
- Pet/CT performed post 2 cycles
Exclusion Criteria
- no PET/CT post 2 cycles performed
- bilirubin >2
- creatinine more then 2
- HIV positivity
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival 5 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
RAMBAM health care Campus
🇮🇱Haifa, Israel